Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly - Wikidata - awgldk - TriplyDB

Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly

Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly

http://www.wikidata.org/entity/Q26777682

about

Advancing Treatment of Pituitary Adenomas through Targeted Molecular Therapies: The Acromegaly and Cushing Disease Paradigms Long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center.Management of aggressive growth hormone secreting pituitary adenomas.The role of combination medical therapy in the treatment of acromegaly.Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance.New medical therapies on the horizon: oral octreotide.Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report.Pharmacokinetic and pharmacodynamic evidence for developing an oral formulation of octreotide against gastric mucosal injury.Novel Somatostatin Receptor Ligands Therapies for Acromegaly.Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats.

P2860

Q26741707-0336EB73-2D45-49C5-9070-23864214BA6A Q38640384-FF6868B1-138D-42D0-B974-8C657E94FF56 Q38781620-F8A7942B-E538-43B2-A097-6EA48CBE4629 Q38927318-32F585FB-E29F-411D-B44B-A2700CDB9A5D Q38990078-F17D390B-CAD1-4242-886C-0964F21A1727 Q39090289-2CB0684E-0DA7-48A5-BA84-2F4D9221F1E9 Q48181953-44097DF6-BB71-46FA-A0DB-CEE6A201C60C Q49499271-D48F1753-5129-4045-99CF-1BD150DF6FD4 Q52643700-EA029B65-F90A-4B10-BE65-FF01D003C79C Q54144943-9669239D-6481-4A2E-AC70-9110755DB454

P2860

Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly

http://www.wikidata.org/entity/Q26777682

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Interpreting biochemical contr ...... statin analogues in acromegaly

@ast

Interpreting biochemical contr ...... statin analogues in acromegaly

@en

Interpreting biochemical contr ...... statin analogues in acromegaly

@nl

type

label

Interpreting biochemical contr ...... statin analogues in acromegaly

@ast

Interpreting biochemical contr ...... statin analogues in acromegaly

@en

Interpreting biochemical contr ...... statin analogues in acromegaly

@nl

prefLabel

Interpreting biochemical contr ...... statin analogues in acromegaly

@ast

Interpreting biochemical contr ...... statin analogues in acromegaly

@en

Interpreting biochemical contr ...... statin analogues in acromegaly

@nl

P1433

Q26777682-5499A016-CE31-4D60-B7ED-621FBBE69B13

P1476

Q26777682-37DA661A-5D72-4D40-B42F-07B9EDD2E588

P2093

Q26777682-17D99C90-26CC-42EC-8A99-4D1EFC70A3C4

Q26777682-1CA685E8-8C97-433F-8DBE-6D63A52F3E5F

Q26777682-74765B23-3FF7-4AE3-B11C-E8A671822378

P275

Q26777682-6EE2E3E5-E228-4996-99AF-251606E82DEA

P2860

Q26777682-0D4A2593-2DED-4996-9F2F-0A560E05DFB8

Q26777682-14CB7B70-45E2-4EC4-B155-4A317208226C

Q26777682-1523F551-741A-483D-9DB9-E7AC04C0B8D7

Q26777682-23016B3B-39DA-4B10-8897-D208B36E1DA9

Q26777682-2B0B12C4-E278-448D-985E-C140A5F591B2

Q26777682-2D3E50A9-7CFB-4757-A7D9-0E4B6310CA0E

Q26777682-3B0E4AE3-2237-4734-BF2F-3E7092036407

Q26777682-3C42B4FC-C6A6-458E-AC8A-61C36667D15A

Q26777682-3D48BAA1-8E50-4B11-91AC-28CCBE76BBAA

Q26777682-411B7405-6FAE-41E2-8D59-BF23677D11D8

P2888

Q26777682-7048DA7A-2650-484A-8144-B236144D40C6

P304

Q26777682-D9A67E4C-30C8-43E3-945B-7FF092CF7CA6

P31

Q26777682-9E5928F2-FED6-42C5-A432-8BE2E601AFB3

Q26777682-D2AAE81E-F1CC-47B3-A358-42BB1F313A0F

P3181

Q26777682-FDD0638B-B223-490B-A88D-5A3F4C3768C6

P356

Q26777682-798B4F97-D02D-4FE3-B08F-E0C6A8D3D41C

P407

Q26777682-A53D617E-7385-429A-98C2-007D548322CD

P433

Q26777682-0EC59529-2F3E-4013-BC51-3321C901F40F

P478

Q26777682-AEFB52D8-1597-4CD9-BA24-B4823BA3B7C7

P50

Q26777682-7846DE60-9D46-4674-B736-CDA34B9220CB

Q26777682-E6AE83F8-7409-42D2-A359-1667C28F0C38

P5008

Q26777682-7386AFC9-6D54-4BF6-9595-CFA9D1404240

P577

Q26777682-5FD4526C-6F22-4124-B348-8FBFE40730E4

Q26777682-66FD140C-9F45-4031-AF03-7B9A3F682110

P5875

Q26777682-2E9CC183-C33B-4619-8897-92EF0510F831

P6179

Q26777682-7AE5FB3F-4C0C-4ECD-934D-4AE08627C4C7

P698

Q26777682-32A529B8-620A-4983-BB78-2DE66CA02639

P921

Q26777682-15DB479B-C531-49AD-8A4F-6989FE2882DB

Q26777682-4B57B4E3-EB9C-4621-9080-42137C11169D

Q26777682-72CFF973-41DA-470E-8615-FC639F1F63D6

Q26777682-87DC4755-3C72-427E-B662-0B47739A102D

Q26777682-9EF10121-FFCD-410B-B16E-6ED28A7D0145

Q26777682-BD155124-90FE-422C-B677-8F86E49C0644

Q26777682-C51FFD9A-F790-40AB-BB81-23D757497B19

Q26777682-ECEFBD1A-9CED-4C2A-92CD-1F5F7A590A7B

P932

Q26777682-D3FAECA4-3671-42CA-B019-3865207DB34F

P3181

P356

S11102-015-0684-Z

P1433

P1476

Interpreting biochemical contr ...... statin analogues in acromegaly

@en

P2093

Leandro Kasuki

http://www.w3.org/2001/XMLSchema#string

Mônica R Gadelha

http://www.w3.org/2001/XMLSchema#string

Renata S Auriemma

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Failure of current laboratory protocols to detect lot-to-lot reagent differences: findings and possible solutions.

Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group.

Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis.

Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension

Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly.

Harmonization of growth hormone measurements with different immunoassays by data adjustment.

Expert consensus document: A consensus on the medical treatment of acromegaly.

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.

Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.

Current concepts in the biochemical assessment of the patient with acromegaly.

P2888

s11102-015-0684-z

P304

235-47

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4250370

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S11102-015-0684-Z

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Rosario Pivonello

Annamaria Colao

P5008

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283444313

http://www.w3.org/2001/XMLSchema#string

P6179

1051359339

http://www.w3.org/2001/XMLSchema#string

P698

26519143

http://www.w3.org/2001/XMLSchema#string

P921

growth hormone secreting pituitary adenoma

polycyclic compound

nerve tissue proteins

P932

4858561

http://www.w3.org/2001/XMLSchema#string